Arrowhead Pharmaceuticals Stock
Arrowhead Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Christopher R. Anzalone
- Employees
- 711
- Market cap
- $7.9 B
- IPO
- 16/12/1993
Arrowhead Pharmaceuticals, Inc. is a healthcare company based in Pasadena, US, dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases. The biotechnology firm primarily leverages RNA interference (RNAi) technology across its extensive therapeutic pipeline. Key…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Arrowhead Pharmaceuticals stock: price history
1D
-4.4%
1W
-10.9%
1M
-15.0%
6M
-19.6%
YTD
-15.8%
1Y
+43.4%
2Y
+164.9%
5Y
-15.5%
10Y
+740.6%
Next earnings date
Next earnings date
24/11/2026 (in 38 days)
Volatility around earnings
~10% stronger price swings than usual
Ask the agents about Arrowhead Pharmaceuticals
Analyst assessment of Arrowhead Pharmaceuticals
PRICE TARGET LOW
US$46.00
CONSENSUS
US$101.56
MEDIAN
US$109.00
PRICE TARGET HIGH
US$126.00
0
STRONG BUY
16
BUY
6
HOLD
0
SELL
0
STRONG SELL
22
TOTAL · Buy
As of: 15/10/2026
Arrowhead Pharmaceuticals stock metrics
P/E
-24.96
P/B
17.22
EV/EBITDA
-65.13
RETURN ON EQUITY
-41.7%
NET MARGIN
-258.2%
DEBT/EQUITY
1.86
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
86.7%
FLOAT SHARES
122,449,260
AVG. DAILY VOLUME (30D)
2,285,379
Insider transactions (SEC)
OLUKOTUN ADEOYE Y
PERRY MICHAEL S
Cohen Matthew Gregory
Lu Hongbo
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -4.4%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Arrowhead Pharmaceuticals stock
What does Arrowhead Pharmaceuticals do?
Arrowhead Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Christopher R. Anzalone, the company employs around 711 people.
The IPO was on 16/12/1993; the stock trades on NASDAQ under the ticker ARWR.
What do analysts say about Arrowhead Pharmaceuticals stock?
22 analysts rate the stock, the consensus is Buy (as of 15/10/2026).
The average price target is US$101.56, ranging from US$46.00 to US$126.00, with a median of US$109.00.
This is an external assessment, not a statement by Market Jury.
When does Arrowhead Pharmaceuticals report next?
The next earnings date is 24/11/2026.
Around past earnings, price swings were roughly 10% stronger than usual.
Does Arrowhead Pharmaceuticals pay a dividend?
No, Arrowhead Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Arrowhead Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Arrowhead Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Arrowhead Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.